NBIX icon

Neurocrine Biosciences
NBIX

Overview Fund Activity

231 hedge funds and large institutions have $3.86B invested in Neurocrine Biosciences in 2016 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 67 increasing their positions, 96 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
231
Holders Change
+19
Holders Change %
+8.96%
% of All Funds
6.17%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.19%
New
42
Increased
67
Reduced
96
Closed
22
Calls
$82.9M
Puts
$13.9M
Net Calls
+$69M
Net Calls Change
+$62.4M

Top Buyers

1
AllianceBernstein
1
AllianceBernstein
Tennessee
$50.2M
2
SIG
2
Senator Investment Group
New York
$38.6M
3
American Century Companies
3
American Century Companies
Missouri
$37.3M
4
JPMorgan Chase & Co
4
JPMorgan Chase & Co
New York
$56.7M
5
PAMU
5
Pictet Asset Management (UK)
United Kingdom
$35M

Top Sellers

1
VAM
1
Visium Asset Management
New York
$219K
2
BFA
2
BlackRock Fund Advisors
California
$88.4M
3
Citadel Advisors
3
Citadel Advisors
Florida
$42.4M
4
O
4
OrbiMed
New York
$82.5M
5
Invesco
5
Invesco
Georgia
$72.9M
Name Holding Trade Value Shares
Change 		Shares
Change %
TRCT
251
Tower Research Capital (TRC)
New York
– -$43K -1,083 Closed
BAM
252
Barrett Asset Management
New York
– -$5K -120 Closed
WA
253
WFG Advisors
Texas
– -$2K -50 Closed
7 8 9 10
11